Navigation Links
Lawson research team working to personalize cancer care
Date:12/12/2011

LONDON, ON - The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.

The Genomics Pathway Sequencing (GPS) study, led by the Princess Margaret Hospital in Toronto, will assess the feasibility of identifying specific genetic markers (mutations) in the DNA of patients' tumours. This information will then be used to identify more targeted treatments.

The Lawson team has developed a process for London where they can obtain a fresh tissue sample from the patient's tumour biopsy. This tissue is sent away to a lab in Toronto where two types of DNA analysis are performed. Within three weeks a report on the cancer's genetic profile is provided to the patient's oncologist. "With this new information, it is hoped the oncologist can deliver a more tailored treatment plan," says Dr. Eric Winquist, lead of the LTCRT and medical oncologist at the London Health Sciences Centre.

Jennifer Malone from London, Ontario was diagnosed with cancer in 2006. Over the next five years, she exhausted all standard cancer treatments. A DNA analysis of her tissue sample identified a mutation in a gene known as KRAS. Fortunately, a study investigating a new drug known to target mutations in KRAS was available at the Princess Margaret Hospital and Jennifer was enrolled.

Since starting the experimental treatment, Jennifer's tumour has regressed and many of her cancer symptoms have improved or disappeared. It is "remarkable and amazing," says Jennifer. "Participating in this study gave me an option where previously no option existed."

While the GPS study is still in early development, the idea of more precisely matching patient treatment to their cancer's individual genetic characteristics holds great promise. "We are excited to be discovering what the future holds for our patients using a personalized approach to ca
'/>"/>

Contact: Julia Capaldi
julia.capaldi@lhsc.on.ca
519-685-8500 x75616
Lawson Health Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
2. Lawson researchers take control of cancer
3. Lawson researchers share in $2.2 million grant
4. Lawson research shows Canadians dont believe their eyes
5. Wistar Institute researcher receives New Innovator award from NIH
6. NC State researchers get to root of parasite genome
7. White Mountain Research Station to host climate change conference
8. Stevens awarded $1M for advanced biofuels research
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... use knowledge about methane production by cold-weather microbes on ... similar, carbon-based microbes that could have evolved on Mars, ... three-year project, funded by a $2.4 million grant from ... program, will be led by biogeochemist Lisa Pratt. Her ...
... for informatics professionals, has weighed in on the Federal ... Office of the National Coordinator,s (ONC) call for comments ... set forth by the U.S. Congress and the Administration. ... MD, summarizes AMIA,s comments simply: "Because health IT ...
... 11 May 2011 - Two new research studies published ... in brain development that emerge as vulnerable individuals develop ... with a deletion of a small section of chromosome ... of abnormalities in the structure of the heart and ...
Cached Biology News:NASA project eyes climate change in Greenland -- with a third eye on Mars 2NASA project eyes climate change in Greenland -- with a third eye on Mars 3AMIA identifies areas to strengthen Federal health IT strategic plan 2Brain development goes off track as vulnerable individuals develop schizophrenia 2
(Date:3/4/2015)... 04, 2015 PRC Clinical, ... San Francisco Bay Area, will exhibit and present at ... 2015 on March 25th and 26th in Tel ... relationships with Israeli life science companies seeking to conduct ... company’s services span all phases of human trials, from ...
(Date:3/4/2015)... March 4, 2015  BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
(Date:3/4/2015)... Launched by the Assistance Publique - ... 2011, ,SARAH, - the French national collaborative randomized ... advanced hepatocellular carcinoma (HCC) has enrolled more than 400 ... a large French study of patients with advanced, inoperable ... patient enrolment, exceeding its 400-patient target, according to its ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... BETHESDA, Md., Oct. 24, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... of D-tagatose and SPX-106) reduced dyslipidemia in new ...
... DLVR Therapeutics Inc. ("DLVR") - a privately-held ... based on its proprietary high density lipoprotein-like nanoparticle ... seed round investment bringing the total raised to ... Innovation joins the University Health Network (UHN) and ...
... 24, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... novel therapeutics targeting cancer metabolism, announced today that Charles Baltic, ... has been appointed to its board of directors. The appointment ... six and the number of independent directors to five. ...
Cached Biology Technology:Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Catalase (Control)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: